康华生物：公司股东孙晚丰、李声友减持计划实施完毕，共减持公司股份约13万股

Group 1 - The core point of the article is that Kanghua Biological has completed a share reduction plan, with shareholders Sun Wanfeng and Li Shengyou reducing their holdings by approximately 130,000 shares, which accounts for 0.0997% of the company's total shares [1] - As of the latest report, Kanghua Biological's market capitalization is 10.7 billion yuan [2] - For the year 2024, the revenue composition of Kanghua Biological is projected to be 92.59% from non-immunization planning vaccines and 7.41% from other sources [1]